The Goldman Sachs Group Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $19.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective lowered by The Goldman Sachs Group from $28.00 to $19.00 in a report issued on Friday morning,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Jefferies Financial Group cut their price objective on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. lowered shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $80.00 to $36.00 in a research report on Thursday. Robert W. Baird cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $40.00 to $16.00 in a research note on Thursday. HC Wainwright dropped their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Royal Bank Of Canada lowered shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $36.63.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $15.30 on Friday. The company’s 50-day moving average price is $27.76 and its 200 day moving average price is $25.00. Ultragenyx Pharmaceutical has a fifty-two week low of $13.81 and a fifty-two week high of $39.89. The company has a market cap of $1.51 billion, a PE ratio of -2.62 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the previous year, the company posted ($1.17) earnings per share. The business’s revenue for the quarter was up 28.5% compared to the same quarter last year. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical will post -3.98 EPS for the current year.

Insider Activity

In related news, Director Corsee Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director directly owned 21,095 shares of the company’s stock, valued at $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Karah Parschauer sold 1,899 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the sale, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co increased its stake in Ultragenyx Pharmaceutical by 2.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after buying an additional 534 shares during the last quarter. Van ECK Associates Corp lifted its position in Ultragenyx Pharmaceutical by 26.1% during the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 549 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 4.7% during the 2nd quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 564 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 0.4% during the 4th quarter. Rafferty Asset Management LLC now owns 157,061 shares of the biopharmaceutical company’s stock worth $3,612,000 after buying an additional 577 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 43.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 751 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.